Overview of Emerging ALK+ NSCLC Treatments

August 12th 2025

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.

Jacob Sands, MD

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

IMM2510/AXN-2510 Combo Yields Preliminary Responses in Advanced NSCLC

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

Tim Cortese

July 31st 2025

Elironrasib Earns FDA Breakthrough Designation for KRAS G12C-Mutant NSCLC

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

The agency’s decision is based on results from the phase 1 RMC-6291-001 clinical trial evaluating elironrasib monotherapy in patients with solid tumors.

July 24th 2025

FDA Approves NGS-Based Companion Diagnostic for Zongertinib in NSCLC

The agency’s decision is based on results from the phase 1 RMC-6291-001 clinical trial evaluating elironrasib monotherapy in patients with solid tumors.

Related Content

August 12th 2025

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.

Jacob Sands, MD

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

IMM2510/AXN-2510 Combo Yields Preliminary Responses in Advanced NSCLC

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Tim Cortese

July 31st 2025

Elironrasib Earns FDA Breakthrough Designation for KRAS G12C-Mutant NSCLC

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

July 24th 2025